Xcopri (Cenobamate) Patent Expiration, LOE Window & CMS Spending
Xcopri (Cenobamate) by Sk Life Science: FDA Orange Book core substance LOE 2032-10-30 (last listed 2039-06-16), 0 AB generics, $316.0M 2024 CMS Part D & Medicaid spend, and $1,180 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Sk Life Science |
| FDA Application & Pathway | N212839 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2032-10-30 |
| Last Listed Patent or Exclusivity Date | 2039-06-16 |
| Orange Book Patents (*PED Extensions) | 2 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $316.0M |
| 2024 Medicare Part D Spend | $164.7M |
| 2024 Medicaid Spend | $151.3M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($1,180 intro WAC) |